Remove Biochemical Assays Remove Science Remove Small Molecule
article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Author Bio: Brett Hall Brett has been Chief Scientific Officer at Immuneering since November 2019.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We often screen using a biochemical assay, but we can conduct cell-based screening as well. We need to build the assays that we need for compound screening.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top 10 Drug Discovery Trends at the Top 20 Pharma

PerkinElmer

Small screens are better than large ones. Biochemical assays have the highest success rate. Small molecules are making a comeback. For the minority of companies working with large molecules and biologics, most said they were in a phase of clinical research. Biologics are booming. Think again.

article thumbnail

Unique self-activating proteins for drug discovery

Drug Target Review

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. Thousand Oaks, CA) in 1999 before returning to academia.

article thumbnail

Accelerating Medicinal Chemistry Cycle Times Through Cloud-Accessible Smart Automated Labs - A Preview of Strateos’ Presentation at SLAS 2022

The Strateos Blog: Drug Discovery

SLAS 2022 is set to be an exciting conference where scientists can come together to learn about the innovative technologies transforming the way life sciences research is executed. Progress from target ID through to IND submission in conventional workflows can take upwards of 6+ years, where success hinges on iterative cycles of DMTA.